MarketCap
Facebook
X
TelegramQuarterly report 2026-Q1
added 05-07-2026
Senseonics Holdings Net Debt 2011-2026 | SENS
Net Debt can be roughly defined as financial liabilities that an entity classifies in the financing section together with the resources available to service those financial liabilities[1]
Net debt is the obligations that remain after deducting all assets and other liabilities from a company or individual. It represents the sum of debts that an organization or person must repay to their creditors or other parties.
Net debt can include various types of obligations such as loans, borrowings, lease liabilities, or credit card payments. It is important to note that net debt does not include current expenses or obligations such as payroll expenses or current bills.
Assessing net debt is an important financial indicator for evaluating the financial position of a company or individual. If net debt significantly exceeds assets, it may indicate financial difficulties and insolvency. In such cases, the company or individual may face difficulties in meeting their obligations and managing their finances.
Net debt can also be used to compare the financial stability of different companies. The lower the net debt relative to assets, the more stable and financially sound they are considered.
Overall, understanding net debt helps evaluate the financial soundness and ability of a company to meet their obligations. It is an important indicator that assists in making decisions about lending, investments, and financial management.
Annual Net Debt Senseonics Holdings
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -4.15 M | -39.5 M | -34.1 M | 21.3 M | 27.2 M | 42.4 M | 20.3 M | -85.9 M | 8.26 M | 6.02 M | -996 | -10 K | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 42.4 M | -85.9 M | -3.18 M |
References
- Pizzo, M., Moscariello, N., & Vinciguerra, R. (2015). Market Incentives and Regulators' Activity Shaping Financial Information: An Analysis of the Net Debt Disclosure in Italy. International Journal of Business and Management, 10(1), 1.
Net Debt of other stocks in the Diagnostics research industry
| Issuer | Net Debt | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Centogene N.V.
CNTG
|
1.18 M | - | -6.23 % | $ 30.6 M |  Germany |
 |
Burning Rock Biotech Limited
BNR
|
-76 M | $ 18.56 | 10.74 % | $ 196 M |  China |
 |
Agilent Technologies
A
|
1.24 B | - | - | $ 34.4 B |  USA |
 |
Castle Biosciences
CSTL
|
-106 M | $ 18.88 | 4.02 % | $ 547 M | USA |
 |
Fulgent Genetics
FLGT
|
-53.3 M | $ 16.19 | 1.44 % | $ 490 M | USA |
|
Akumin
AKU
|
1.21 B | - | -17.87 % | $ 25.9 M |  Canada |
 |
Interpace Biosciences
IDXG
|
-1.32 M | $ 1.8 | -5.26 % | $ 7.96 M | USA |
 |
Aspira Women's Health
AWH
|
-512 K | - | -6.19 % | $ 10.5 M | USA |
 |
Accelerate Diagnostics
AXDX
|
-33.3 M | - | -61.36 % | $ 2.46 M | USA |
 |
Biocept
BIOC
|
-11.2 M | - | -13.05 % | $ 7.29 M | USA |
 |
Oxford Immunotec Global PLC
OXFD
|
-173 M | - | - | $ 562 M |  Britain |
 |
CareDx, Inc
CDNA
|
-39.2 M | $ 20.49 | -0.58 % | $ 1.09 B | USA |
 |
Chembio Diagnostics
CEMI
|
-17.2 M | - | 0.22 % | $ 16.8 M | USA |
 |
Medpace Holdings
MEDP
|
-360 M | $ 419.17 | -1.08 % | $ 12.1 B | USA |
 |
Check-Cap Ltd.
CHEK
|
-3.13 M | - | - | $ 9.42 M |  Israel |
 |
Lantheus Holdings
LNTH
|
213 M | - | - | $ 6.5 B | USA |
 |
Mettler-Toledo International
MTD
|
2.06 B | $ 1 041.91 | 1.75 % | $ 21.5 B |  Schweiz |
 |
Myriad Genetics
MYGN
|
-22.8 M | $ 3.62 | -2.95 % | $ 335 M | USA |
 |
HTG Molecular Diagnostics
HTGM
|
-11.2 M | - | -20.0 % | $ 1.06 M | USA |
 |
Co-Diagnostics
CODX
|
-10.6 M | $ 1.63 | 1.87 % | $ 2.17 M | USA |
 |
NeoGenomics
NEO
|
187 M | $ 8.36 | 1.21 % | $ 1.07 B | USA |
 |
National Research Corporation
NRC
|
71.3 M | $ 18.93 | 1.39 % | $ 424 M | USA |
 |
Natera
NTRA
|
-177 M | $ 196.91 | 0.81 % | $ 19.4 B | USA |
 |
Global Cord Blood Corporation
CO
|
-6.07 B | - | - | $ 399 M | China |
 |
Fluidigm Corporation
FLDM
|
-5.38 M | - | 1.08 % | $ 308 M | USA |
 |
Genetic Technologies Limited
GENE
|
-11.1 M | - | - | $ 7.1 B |  Australia |
 |
Genetron Holdings Limited
GTH
|
-1.35 B | - | 0.12 % | $ 80.1 M | China |
 |
DermTech
DMTK
|
-33.6 M | - | -11.32 % | $ 2.94 M | USA |
 |
Charles River Laboratories International
CRL
|
1.98 B | $ 159.12 | -2.29 % | $ 7.89 B | USA |
 |
PRA Health Sciences, Inc.
PRAH
|
769 M | - | - | $ 10.7 B | USA |
 |
Koninklijke Philips N.V.
PHG
|
2.48 B | $ 25.5 | -0.51 % | $ 24.2 B |  Niderland |
 |
Enzo Biochem
ENZ
|
-51.3 M | - | -8.98 % | $ 14.8 K | USA |
 |
Exact Sciences Corporation
EXAS
|
-916 M | - | - | $ 19.8 B | USA |
 |
Personalis
PSNL
|
-117 M | $ 6.71 | 5.01 % | $ 599 M | USA |
 |
Guardant Health
GH
|
1.15 B | $ 98.66 | 0.19 % | $ 12.4 B | USA |
 |
Heska Corporation
HSKA
|
-153 M | - | - | $ 1.31 B | USA |
 |
ICON Public Limited Company
ICLR
|
4.63 B | $ 117.09 | -0.25 % | $ 9.66 B |  Irlanda |
 |
Illumina
ILMN
|
-494 M | $ 143.24 | -1.21 % | $ 22.8 B | USA |
 |
Soleno Therapeutics
SLNO
|
-19.5 M | $ 52.99 | 0.08 % | $ 2.69 B | USA |
 |
Trinity Biotech plc
TRIB
|
55.4 M | $ 0.58 | -1.08 % | $ 208 M | Irlanda |
 |
QIAGEN N.V.
QGEN
|
1.31 B | - | - | $ 10.6 B | Niderland |
 |
Twist Bioscience Corporation
TWST
|
-107 M | $ 52.95 | -2.65 % | $ 3.17 B | USA |
 |
Biomerica
BMRA
|
-1.94 M | $ 2.41 | 7.11 % | $ 5.54 M | USA |
 |
Thermo Fisher Scientific
TMO
|
29.6 B | $ 448.21 | 0.49 % | $ 169 B | USA |
 |
Laboratory Corporation of America Holdings
LH
|
4.74 B | $ 254.02 | -0.16 % | $ 21.1 B | USA |
 |
Waters Corporation
WAT
|
391 M | $ 333.21 | -0.51 % | $ 19.8 B | USA |
 |
Celcuity
CELC
|
-28.1 M | $ 134.72 | 8.23 % | $ 6.3 B | USA |
 |
Motus GI Holdings
MOTS
|
-3.55 M | - | -34.28 % | $ 263 K | Israel |
 |
Neogen Corporation
NEOG
|
751 M | $ 8.43 | -2.99 % | $ 1.83 B | USA |